Protocols

Quick hits from around the biopharma web

More Protocols

Thumbs Up/Down

More Thumbs Up/Down

Deep dives

Marco

Hot BioTwitter bot - last updated ago

Most Viral

These Americans Hated the Health Law. Until the Idea of Repeal Sank In.

New York Times Abby Goodnough, Kate Zernike a day

Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both

NEJM a day

Nutrition science isn't broken, it's just wicked hard

Washington Post a day

One cancer breakthrough is on its way. Here's what's coming next

STAT a day

Founder of Purdue Pharma Made a Fortune From Addictive Painkiller OxyContin, Donated Generously to Charity

WSJ a day

Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma - Bayer News

Bayer Bayer AG Communications a day

GlaxoSmithKline's new CEO prepares to trim drug pipeline

Reuters Ben Hirschler a day

Why John McCain's Brain Tumor Type Is So Hard To Treat

Forbes a day

UPDATE 1-U.S. jury sides with Amphastar over Momenta in drug patent trial

Reuters Reuters Editorial a day

Peer Review: Why would Laurie Glimcher swap a seat on Bristol-Myers' board for one on GSK's?

ENDPOINTS NEWS John Carroll a day

More links

Latest

WSJ

Sean Spicer Faced Myriad Obstacles During Dramatic​White House​Rise and Fall

Science Translational Medicine

Rise of the Electron Beams

Twitter

The Daytrade™ on Twitter: $DMPI HUGE - CEO Jeffrey Bacha, In Benzinga Interview, Says US Senator John McCain's Doctors May Seek Access To The Co.'s VAL083 Treatment

Evaluate Pharma

EvaluatePharma World Preview 2017, Outlook to 2022

Nature Genetics

Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease

SEC

Nektar Form 8-K

Renaissancecapital

Bone Disease Biotech Clementia Pharmaceuticals Sets Terms For $100 Million IPO

MedCity News

Can passive remote patient monitoring sensors move the cost needle for seniors aging in place?

CNN

Why cancer is not a war, fight, or battle

science-aaas

Promote scientific integrity via journal peer review data

Hot This Week

1

Los Angeles Times

An overdose, a young companion, drug-fueled parties: The secret life of then-USC med school dean

2

STAT

New Vertex drugs show big gains in tough-to-treat cystic fibrosis patients

3

Forbes

New Vertex Drugs Show Dramatic Benefit In Cystic Fibrosis

4

ProPublica

The Myth of Drug Expiration Dates

5

BusinessWire

Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)

6

New York Times

These Americans Hated the Health Law. Until the Idea of Repeal Sank In.

7

ENDPOINTS NEWS

King cancer: The top 10 therapeutic areas in biopharma R&D

8

NEJM

Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both

9

Washington Post

Nutrition science isn't broken, it's just wicked hard

10

STAT

One cancer breakthrough is on its way. Here's what's coming next

Follow Marco